Kim DK - Search Results

1

EW-7197 Attenuates the Progression of Diabetic Nephropathy in db/db Mice through Suppression of Fibrogenesis and Inflammation.

Ha KB, Sangartit W, Jeong AR, Lee ES, Kim HM, Shim S, Kukongviriyapan U, Kim DK, Lee EY, Chung CH. Ha KB, et al. Among authors: kim hm, kim dk. Endocrinol Metab (Seoul). 2022 Feb;37(1):96-111. doi: 10.3803/EnM.2021.1305. Epub 2022 Feb 28. Endocrinol Metab (Seoul). 2022. PMID: 35255604 Free PMC article.

2

EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling.

Park SA, Kim MJ, Park SY, Kim JS, Lee SJ, Woo HA, Kim DK, Nam JS, Sheen YY. Park SA, et al. Among authors: kim dk, kim js, kim mj. Cell Mol Life Sci. 2015 May;72(10):2023-39. doi: 10.1007/s00018-014-1798-6. Epub 2014 Dec 9. Cell Mol Life Sci. 2015. PMID: 25487606

3

TGF-β Type I Receptor Kinase Inhibitor EW-7197 Suppresses Cholestatic Liver Fibrosis by Inhibiting HIF1α-Induced Epithelial Mesenchymal Transition.

Kim MJ, Park SA, Kim CH, Park SY, Kim JS, Kim DK, Nam JS, Sheen YY. Kim MJ, et al. Among authors: kim ch, kim dk, kim js. Cell Physiol Biochem. 2016;38(2):571-88. doi: 10.1159/000438651. Epub 2016 Feb 5. Cell Physiol Biochem. 2016. PMID: 26845171 Free article.

4

Discovery of (E)-3-(3-((2-Cyano-4'-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis.

Shim S, Krishnaiah M, Sankham MR, Kim I, Lee Y, Shin I, Oh AR, Lee HJ, Vu TNL, Park J, Choi S, Park S, Kwon Y, Fang S, Kim DK. Shim S, et al. Among authors: kim dk, kim i. J Med Chem. 2022 Jul 28;65(14):9974-10000. doi: 10.1021/acs.jmedchem.2c00641. Epub 2022 Jul 7. J Med Chem. 2022. PMID: 35797110

5

Different routes of administering EW-7197 versus EW-7197⋅HBr for preventing peritoneal adhesion in a rat model.

Zeng CH, Kim SH, Kang JM, Park Y, Won DS, Kim JW, Ryu DS, Shim S, Kim DK, Shin JH, Park JH. Zeng CH, et al. Among authors: kim sh, kim dk, kim jw. Surgery. 2023 Apr;173(4):1008-1014. doi: 10.1016/j.surg.2022.11.016. Epub 2022 Dec 26. Surgery. 2023. PMID: 36577598

6

Beneficial Effects of a Curcumin Derivative and Transforming Growth Factor-β Receptor I Inhibitor Combination on Nonalcoholic Steatohepatitis.

Ha KB, Lee ES, Park NW, Jo SH, Shim S, Kim DK, Ahn CM, Chung CH. Ha KB, et al. Among authors: kim dk. Diabetes Metab J. 2023 Jul;47(4):500-513. doi: 10.4093/dmj.2022.0110. Epub 2023 Apr 25. Diabetes Metab J. 2023. PMID: 37096379 Free PMC article.

7

Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer.

Lee JE, Lee P, Yoon YC, Han BS, Ko S, Park MS, Lee YJ, Kim SE, Cho YJ, Lim JH, Ryu JK, Shim S, Kim DK, Jung KH, Hong SS. Lee JE, et al. Among authors: kim se, kim dk. Biomed Pharmacother. 2023 Jun;162:114716. doi: 10.1016/j.biopha.2023.114716. Epub 2023 Apr 20. Biomed Pharmacother. 2023. PMID: 37086509 Free article.

8

EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.

Park CY, Son JY, Jin CH, Nam JS, Kim DK, Sheen YY. Park CY, et al. Among authors: kim dk. Eur J Cancer. 2011 Nov;47(17):2642-53. doi: 10.1016/j.ejca.2011.07.007. Epub 2011 Aug 16. Eur J Cancer. 2011. PMID: 21852112

9

Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.

Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Rao KS, Lee HJ, Park SJ, Park HJ, Lee K, Sheen YY, Kim DK. Jin CH, et al. Among authors: kim dk. J Med Chem. 2014 May 22;57(10):4213-38. doi: 10.1021/jm500115w. Epub 2014 May 13. J Med Chem. 2014. PMID: 24786585

10

EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis.

Son JY, Park SY, Kim SJ, Lee SJ, Park SA, Kim MJ, Kim SW, Kim DK, Nam JS, Sheen YY. Son JY, et al. Among authors: kim sw, kim sj, kim dk, kim mj. Mol Cancer Ther. 2014 Jul;13(7):1704-16. doi: 10.1158/1535-7163.MCT-13-0903. Epub 2014 May 9. Mol Cancer Ther. 2014. PMID: 24817629

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,805 results

Search Page